DOCSLIB.ORG

Receptors for Purines and Pyrimidines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Receptors for Purines and Pyrimidines 0031-6997/98/5003-0413$03.00/0 PHARMACOLOGICAL REVIEWS Vol. 50, No. 3 Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. Receptors for Purines and Pyrimidines VERA RALEVICa AND GEOFFREY BURNSTOCK School of Biomedical Sciences (V.R.), Queen’s Medical Centre, University of Nottingham, Nottingham, England; Autonomic Neuroscience Institute (G.B.), Royal Free Hospital School of Medicine, London, England This paper is available online at http://www.pharmrev.org I. Introduction........................................................................... 415 A. Overview ....................................................................... 415 B. Historical perspective ............................................................ 416 II. Adenosine/P1 Receptors ................................................................ 418 A. Introduction..................................................................... 418 B. Structure ....................................................................... 419 C. Agonists ........................................................................ 420 D. Antagonists ..................................................................... 421 III. A1 receptor............................................................................ 421 A. Cloned A1 receptors.............................................................. 422 B. Signal transduction mechanisms .................................................. 422 C. Desensitization .................................................................. 423 D. Sensitization/up-regulation ....................................................... 424 E. Agonists ........................................................................ 424 F. Antagonists ..................................................................... 424 G. Distribution and biological effects ................................................. 424 IV. A2A receptor .......................................................................... 427 A. Cloned A2A receptors............................................................. 427 B. Signal transduction mechanisms .................................................. 427 C. Desensitization .................................................................. 428 D. Sensitization/up-regulation ....................................................... 428 E. Agonists ........................................................................ 428 F. Antagonists ..................................................................... 429 G. Distribution and biological effects ................................................. 429 V. A2B receptor .......................................................................... 431 A. Cloned A2B receptors............................................................. 431 B. Signal transduction mechanisms .................................................. 432 C. Desensitization .................................................................. 432 D. Agonists and antagonists ......................................................... 432 E. Distribution and biological effects ................................................. 433 VI. A3 receptor............................................................................ 433 A. Cloned A3 receptors.............................................................. 433 B. Signal transduction mechanisms .................................................. 434 C. Desensitization .................................................................. 434 D. Up-regulation ................................................................... 434 E. Agonists ........................................................................ 434 F. Antagonists ..................................................................... 435 G. Distribution and biological effects ................................................. 435 VII. Integrated effects of adenosine/P1 receptors .............................................. 436 VIII. P2 receptors........................................................................... 437 A. Introduction..................................................................... 437 B. Agonists ........................................................................ 439 C. Antagonists ..................................................................... 440 1. Suramin ....................................................................... 440 a Address for correspondence: Vera Ralevic, School of Biomedical Sciences, Queen’s Medical Centre, University of Nottingham, Notting- ham NG7 2UH, England. E-mail: [email protected] 413 414 RALEVIC AND BURNSTOCK 2. NF023 (symmetrical 39-urea of 8-(benzamido)naphthalene-1,3,5-trisulfonic acid) ...... 441 3. NF279 (8,89-(carbonylbis(imino-4,1-phenylenecarbonylimino-4,1- phenylenecarbonylimino))bis(1,3,5-naphthalenetrisulfonic acid)) ..................... 443 4. Pyridoxal-5-phosphate (P5P)..................................................... 443 5. PPADS (pyridoxalphosphate-6-azophenyl-29,49-disulfonic acid) ...................... 443 6. Iso-PPADS..................................................................... 444 7. Reactive blue 2................................................................. 444 8. Reactive red ................................................................... 444 9. Trypan blue.................................................................... 444 10. Evans blue..................................................................... 444 11. DIDS (4,49-diisothiocyanatostilbene-2,29-disulfonate) ............................... 444 12. Arylazidoaminopropionyl ATP (ANAPP3) ......................................... 445 13. 2-Alkylthio derivatives of ATP ................................................... 445 14. 59-p-Fluorosulfonyl benzoyladenosine ............................................. 445 IX. P2X receptors ......................................................................... 445 A. Structure ....................................................................... 445 B. Cloned P2X receptors ............................................................ 447 1. P2X1 receptor .................................................................. 447 2. P2X2 receptor .................................................................. 447 3. P2X3 receptor .................................................................. 448 4. P2X4 receptor .................................................................. 448 5. P2X5 receptor .................................................................. 448 6. P2X6 receptor .................................................................. 449 7. P2X7 receptor .................................................................. 449 C. Signal transduction mechanisms .................................................. 449 D. Desensitization .................................................................. 449 E. Agonists and antagonists ......................................................... 451 F. Distribution and biological effects ................................................. 453 1. Central nervous system (CNS) ................................................... 454 2. Sensory nerves ................................................................. 454 3. Peripheral nervous system (PNS) ................................................ 454 4. Smooth muscle ................................................................. 455 5. Blood cells ..................................................................... 456 X. P2X7 and endogenous P2X7-like (or P2Z) receptors ........................................ 456 A. Structure ....................................................................... 456 B. Cloned P2X7 receptors ........................................................... 456 C. Signal transduction mechanisms .................................................. 457 D. Desensitization .................................................................. 457 E. Agonists ........................................................................ 457 F. Antagonists ..................................................................... 457 G. Distribution and biological effects ................................................. 457 XI. P2Y receptors ......................................................................... 458 A. Structure ....................................................................... 458 XII. P2Y1 and endogenous P2Y1-like receptors ................................................ 459 A. Cloned P2Y1 receptors ........................................................... 459 B. Signal transduction mechanisms .................................................. 459 C. Desensitization .................................................................. 460 D. Agonists ........................................................................ 461 E. Antagonists ..................................................................... 461 F. Heterogeneity of P2Y1 and endogenous P2Y1-like receptors .......................... 461 G. Distribution and biological effects ................................................. 462 XIII. P2Y2 and endogenous P2Y2-like receptor................................................. 464 A. Cloned P2Y2 receptors ........................................................... 464 B. Signal transduction mechanisms .................................................. 464 C. Desensitization .................................................................
Load more

Recommended publications
  • Expression of Purinergic Receptors on Microglia in the Animal Model Of
    www.nature.com/scientificreports OPEN Expression of purinergic receptors on microglia in the animal model of choroidal neovascularisation Lu Li1*, Juejun Liu1, Amin Xu1, Peter Heiduschka2, Nicole Eter2 & Changzheng Chen1 To investigate the efect of P2 receptor on microglia and its inhibitor PPADS on choroidal neovascularization. Forty CX3CR1GFP/+ mice were randomly divided into 8 groups. In addition to the normal group, the rest of groups were receiving laser treatment. The retina and choroid from the second, third, fourth and ffth group of mice were taken in the 1, 4, 7, 14 days after laser treatment. The mice in the sixth and seventh group received intravitreal injection of 2 µl PPADS or PBS respectively immediately after laser treatment. The mice in the eighth group received topical application of PPADS once per day of three days. The mice in sixth, seventh and eighth group received AF and FFA examination on the fourth day after laser treatment. Immunofuorescence histochemical staining and real-time quantitative PCR were used to evaluate P2 expression and its efect on choroidal neovascularization. After laser treatment, activated microglia can express P2 receptors (P2X4, P2X7, P2Y2 and P2Y12). The expression of P2 increased on the frst day after laser damage, peaked on the fourth day (tP2X4 = 6.05, tP2X7 = 2.95, tP2Y2 = 3.67, tP2Y12 = 5.98, all P < 0.01), and then decreased. After PPADS inhibition, compared with the PBS injection group, the mRNA of P2X4, P2X7, P2Y2 and P2Y12 were decreased signifcantly in the PPADS injection group (tP2X4 = 5.54, tP2X7 = 9.82, tP2Y2 = 3.86, tP2Y12 = 7.91, all P < 0.01) and the PPADS topical application group (tP2X4 = 3.24, tP2X7 = 5.89, tP2Y2 = 6.75, tP2Y12 = 4.97, all P < 0.01).
    [Show full text]
  • Issn: 2455-7080
    ISSN: 2455-7080 Contents lists available at http://www.albertscience.com ASIO Journal of Experimental Pharmacology & Clinical Research (ASIO-JEPCR) Volume 1, Issue 1, 2016, 01-07 AN OVERVIEW OF TUBERCULOSIS MANAGEMENT: MECHANISM AND THERAPEUTIC APPLICATIONS Nidhi Singh Joint Replacement Surgery Research Unit, Fortis Escort Hospital, Jaipur, Rajasthan, India ARTICLE INFO ABSTRACT Tuberculosis infections have exceptional virulence factors compared to other Review Article History pathogens and they infect host cell and persist inside phagosomes. First Received: 29 October, 2015 symptoms of active pulmonary TB can include weight loss, night sweats, fever, Accepted: 05 January, 2016 and loss of appetite etc. The infection can either go into remission or become more serious with onset of chest pain and coughing up bloody sputum. The exact Corresponding Author: symptoms of extra-pulmonary TB vary according to the site of infection in the body. The Mantoux tuberculin skin test, also called as the PPD (purified protein Nidhi Singh derivative) test, is primarily used to identify TB infection. According to their clinical utility the anti-TB drugs can be divided into, two categories; one is first Joint Replacement Surgery line, these drugs have high anti-tubercular efficiency as well as low toxicity; are Research Unit, Fortis Escort used routinely, as for examples- Rifampin (R), Isoniazid (H), Streptomycin (S), Hospital, Jaipur, Rajasthan, India Pyrazinamide (Z), Ethambutol (E) and another is second line, these drugs have either low anti-tubercular efficacy or high toxicity or both; are used in special circumstances only. There are six classes of second-line drugs likes amino Email: [email protected] glycosides, fluoro quinolones, polypeptides, thioamides, cycloserine, p-amino salicylic acid.
    [Show full text]
  • The Inflammasome Promotes Adverse Cardiac Remodeling Following Acute
    The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse Eleonora Mezzaromaa,b,c,1, Stefano Toldoa,b,1, Daniela Farkasb, Ignacio M. Seropiana,b,c, Benjamin W. Van Tassellb,c, Fadi N. Sallouma, Harsha R. Kannana,b, Angela C. Mennaa,b, Norbert F. Voelkela,b, and Antonio Abbatea,b,2 aVCU Pauley Heart Center, bVCU Victoria Johnson Center, and cSchool of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298 Edited* by Charles A. Dinarello, University of Colorado Denver, Aurora, CO, and approved October 19, 2011 (received for review May 31, 2011) Acute myocardial infarction (AMI) initiates an intense inflamma- and increased caspase-1–mediated cell death in a more severe tory response that promotes cardiac dysfunction, cell death, and model of ischemia without reperfusion. We also describe phar- ventricular remodeling. The molecular events underlying this macologic inhibition of cryopyrin and P2X7 to prevent inflam- inflammatory response, however, are incompletely understood. masome formation and ameliorate cardiac damage as a potential In experimental models of sterile inflammation, ATP released from basis for translational investigation. dying cells triggers, through activation of the purinergic P2X7 receptor, the formation of the inflammasome, a multiprotein Results complex necessary for caspase-1 activation and amplification of Caspase-1 Is Activated in AMI. Caspase-1 mRNA synthesis in- the inflammatory response. Here we describe the presence of the creased severalfold in the heart at 3 and 7 d after AMI (Fig. S1). inflammasome in the heart in an experimental mouse model of Caspase-1 activation was also increased at 7 d as measured by AMI as evidenced by increased caspase-1 activity and cytoplasmic increased procaspase-1, increased cleaved caspase-1, and in- aggregates of the three components of the inflammasome—apo- creased cleaved/procaspase-1 ratio (Fig.
    [Show full text]
  • Chloroquine Stimulates Cl Secretion by Ca Activated Cl Channels in Rat
    Chloroquine Stimulates Cl2 Secretion by Ca2+ Activated Cl2 Channels in Rat Ileum Ning Yang1., Zhen Lei2., Xiaoyu Li1, Junhan Zhao1, Tianjian Liu1, Nannan Ning1, Ailin Xiao1, Linlin Xu1, Jingxin Li1* 1 Department of Physiology, Shandong University School of Medicine, Jinan, China, 2 Department of Anesthesiology, Qilu Hospital, Shandong University, Jinan, China Abstract Chloroquine (CQ), a bitter tasting drug widely used in treatment of malaria, is associated gastrointestinal side effects including nausea or diarrhea. In the present study, we investigated the effect of CQ on electrolyte transport in rat ileum using the Ussing chamber technique. The results showed that CQ evoked an increase in short circuit current (ISC) in rat ileum at lower concentration (#561024 M ) but induced a decrease at higher concentrations ($1023 M). These responses were not affected by tetrodotoxin (TTX). Other bitter compounds, such as denatoniumbenzoate and quinine, exhibited similar 24 + effects. CQ-evoked increase in ISC was partly reduced by amiloride(10 M), a blocker of epithelial Na channels. Furosemide 24 + + 2 2 (10 M), an inhibitor of Na -K -2Cl co-transporter, also inhibited the increased ISC response to CQ, whereas another Cl channel inhibitor, CFTR(inh)-172(1025M), had no effect. Intriguingly, CQ-evoked increases were almost completely abolished by niflumic acid (1024M), a relatively specific Ca2+-activated Cl2 channel (CaCC) inhibitor. Furthermore, other CaCC inhibitors, such as DIDS and NPPB, also exhibited similar effects. CQ-induced increases in ISC were also abolished by thapsigargin(1026M), a Ca2+ pump inhibitor and in the absence of either Cl2 or Ca2+ from bathing solutions. Further studies demonstrated that T2R and CaCC-TMEM16A were colocalized in small intestinal epithelial cells and the T2R agonist CQ evoked an increase of intracelluar Ca2+ in small intestinal epithelial cells.
    [Show full text]
  • Advances in Non-Dopaminergic Treatments for Parkinson's Disease
    REVIEW ARTICLE published: 22 May 2014 doi: 10.3389/fnins.2014.00113 Advances in non-dopaminergic treatments for Parkinson’s disease Sandy Stayte 1,2 and Bryce Vissel 1,2* 1 Neuroscience Department, Neurodegenerative Disorders Laboratory, Garvan Institute of Medical Research, Sydney, NSW, Australia 2 Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia Edited by: Since the 1960’s treatments for Parkinson’s disease (PD) have traditionally been directed Eero Vasar, University of Tartu, to restore or replace dopamine, with L-Dopa being the gold standard. However, chronic Estonia L-Dopa use is associated with debilitating dyskinesias, limiting its effectiveness. This has Reviewed by: resulted in extensive efforts to develop new therapies that work in ways other than Andrew Harkin, Trinity College Dublin, Ireland restoring or replacing dopamine. Here we describe newly emerging non-dopaminergic Sulev Kõks, University of Tartu, therapeutic strategies for PD, including drugs targeting adenosine, glutamate, adrenergic, Estonia and serotonin receptors, as well as GLP-1 agonists, calcium channel blockers, iron Pille Taba, Universoty of Tartu, chelators, anti-inflammatories, neurotrophic factors, and gene therapies. We provide a Estonia Pekka T. Männistö, University of detailed account of their success in animal models and their translation to human clinical Helsinki, Finland trials. We then consider how advances in understanding the mechanisms of PD, genetics, *Correspondence: the possibility that PD may consist of multiple disease states, understanding of the Bryce Vissel, Neuroscience etiology of PD in non-dopaminergic regions as well as advances in clinical trial design Department, Neurodegenerative will be essential for ongoing advances. We conclude that despite the challenges ahead, Disorders Laboratory, Garvan Institute of Medical Research, patients have much cause for optimism that novel therapeutics that offer better disease 384 Victoria Street, Darlinghurst, management and/or which slow disease progression are inevitable.
    [Show full text]
  • The Interaction of Selective A1 and A2A Adenosine Receptor Antagonists with Magnesium and Zinc Ions in Mice: Behavioural, Biochemical and Molecular Studies
    International Journal of Molecular Sciences Article The Interaction of Selective A1 and A2A Adenosine Receptor Antagonists with Magnesium and Zinc Ions in Mice: Behavioural, Biochemical and Molecular Studies Aleksandra Szopa 1,* , Karolina Bogatko 1, Mariola Herbet 2 , Anna Serefko 1 , Marta Ostrowska 2 , Sylwia Wo´sko 1, Katarzyna Swi´ ˛ader 3, Bernadeta Szewczyk 4, Aleksandra Wla´z 5, Piotr Skałecki 6, Andrzej Wróbel 7 , Sławomir Mandziuk 8, Aleksandra Pochodyła 3, Anna Kudela 2, Jarosław Dudka 2, Maria Radziwo ´n-Zaleska 9, Piotr Wla´z 10 and Ewa Poleszak 1,* 1 Chair and Department of Applied and Social Pharmacy, Laboratory of Preclinical Testing, Medical University of Lublin, 1 Chod´zkiStreet, PL 20–093 Lublin, Poland; [email protected] (K.B.); [email protected] (A.S.); [email protected] (S.W.) 2 Chair and Department of Toxicology, Medical University of Lublin, 8 Chod´zkiStreet, PL 20–093 Lublin, Poland; [email protected] (M.H.); [email protected] (M.O.); [email protected] (A.K.) [email protected] (J.D.) 3 Chair and Department of Applied and Social Pharmacy, Medical University of Lublin, 1 Chod´zkiStreet, PL 20–093 Lublin, Poland; [email protected] (K.S.);´ [email protected] (A.P.) 4 Department of Neurobiology, Polish Academy of Sciences, Maj Institute of Pharmacology, 12 Sm˛etnaStreet, PL 31–343 Kraków, Poland; [email protected] 5 Department of Pathophysiology, Medical University of Lublin, 8 Jaczewskiego Street, PL 20–090 Lublin, Poland; [email protected] Citation: Szopa, A.; Bogatko, K.; 6 Department of Commodity Science and Processing of Raw Animal Materials, University of Life Sciences, Herbet, M.; Serefko, A.; Ostrowska, 13 Akademicka Street, PL 20–950 Lublin, Poland; [email protected] M.; Wo´sko,S.; Swi´ ˛ader, K.; Szewczyk, 7 Second Department of Gynecology, 8 Jaczewskiego Street, PL 20–090 Lublin, Poland; B.; Wla´z,A.; Skałecki, P.; et al.
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]
  • Development of Megakaryoblastic Leukaemia in Runx1-Evi1 Knock-In Chimaeric Mouse
    Letter to the Editor 1458 control. The Mcl-1-specific T-cell clone did not kill this cell line Ms. Bodil K. Jakobsen, Department of Clinical Immunology, (Figure 1c). University Hospital, Copenhagen, for HLA-typing of patient blood The lower rates of relapse in allogeneic transplantation samples. This study was supported by grants from the Danish compared with autologous bone marrow transplantation, the Medical Research Council, The Novo Nordisk Foundation, The striking clinical benefit of donor-lymphocyte infusions as well as Danish Cancer Society, The John and Birthe Meyer Foundation, the finding that human T cells can destroy chemotherapy- and Danish Cancer Research Foundation. resistant cell lines from chronic myeloid leukemia and multiple RB Sørensen1, OJ Nielsen2, P thor Straten1 and MH Andersen1 myeloma, have prompted development of immunotherapeutic 1 strategies against hematological cancers.3 Among these ap- Tumor Immunology Group, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark and proaches, active specific immunization or vaccination is 2Department of Hematology, State University Hospital, emerging as a valuable tool to boost the adaptive immune Copenhagen, Denmark. system against malignant cells. In this regard, the identification E-mail: [email protected] of leukemia-associated antigens is crucial. However, very few antigens are characterized in a conceptual framework in which the biology, microenvironment, and conventional disease management have been taken into consideration. Myeloid cell References factor-1 (Mcl-1) is a death-inhibiting member of the Bcl-2 family that is expressed in early monocyte differentiation. Elevated 1 Andersen MH, Becker JC, thor Straten P. The anti-apoptotic member levels of Mcl-1 have been reported for a number of solid and of the Bcl-2 family Mcl-1 is a CTL target in cancer patients.
    [Show full text]
  • A Differential Role for the Adenosine A2A Receptor in Opiate Reinforcement Vs Opiate-Seeking Behavior
    Neuropsychopharmacology (2009) 34, 844–856 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $32.00 www.neuropsychopharmacology.org A Differential Role for the Adenosine A2A Receptor in Opiate Reinforcement vs Opiate-Seeking Behavior 1,2 2 1,3 4 Robyn Mary Brown , Jennifer Lynn Short , Michael Scott Cowen , Catherine Ledent and ,1,3 Andrew John Lawrence* 1Brain Injury and Repair Group, Howard Florey Institute, University of Melbourne, Parkville, VIC, Australia; 2Monash Institute of Pharmaceutical 3 4 Sciences, Parkville, VIC, Australia; Centre for Neuroscience, University of Melbourne, Parkville, VIC, Australia; Faculte de Medecine, Institut de Recherche Interdisciplinaire, Universite de Bruxelles, Brussels, Belgium The adenosine A2A receptor is specifically enriched in the medium spiny neurons that make up the ‘indirect’ output pathway from the ventral striatum, a structure known to have a crucial, integrative role in processes such as reward, motivation, and drug-seeking behavior. In the present study we investigated the impact of adenosine A receptor deletion on behavioral responses to morphine in a number of 2A reward-related paradigms. The acute, rewarding effects of morphine were evaluated using the conditioned place preference paradigm. Operant self-administration of morphine on both fixed and progressive ratio schedules as well as cue-induced drug-seeking was assessed. In addition, the acute locomotor response to morphine as well as sensitization to morphine was evaluated. Decreased morphine self- administration and breakpoint in A2A knockout mice was observed. These data support a decrease in motivation to consume the drug, perhaps reflecting diminished rewarding effects of morphine in A2A knockout mice. In support of this finding, a place preference to morphine was not observed in A knockout mice but was present in wild-type mice.
    [Show full text]
  • Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson’S Disease
    The Journal of Neuroscience, 2001, Vol. 21 RC143 1of6 Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson’s Disease Jiang-Fan Chen,1 Kui Xu,1 Jacobus P. Petzer,2 Roland Staal,3 Yue-Hang Xu,1 Mark Beilstein,1 Patricia K. Sonsalla,3 Kay Castagnoli,2 Neal Castagnoli Jr,2 and Michael A. Schwarzschild1 1Molecular Neurobiology Laboratory, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts 02129, 2Harvey W. Peters Center, Department of Chemistry, Virginia Tech, Blacksburg, Virginia 24061-0212, and 3Department of Neurology, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08854-5635 Recent epidemiological studies have established an associa- 58261), 3,7-dimethyl-1-propargylxanthine, and (E)-1,3-diethyl-8 tion between the common consumption of coffee or other (KW-6002)-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H- caffeinated beverages and a reduced risk of developing Parkin- purine-2,6-dione) (KW-6002) and by genetic inactivation of the A2A son’s disease (PD). To explore the possibility that caffeine helps receptor, but not by A1 receptor blockade with 8-cyclopentyl-1,3- prevent the dopaminergic deficits characteristic of PD, we in- dipropylxanthine, suggesting that caffeine attenuates MPTP tox- vestigated the effects of caffeine and the adenosine receptor icity by A2A receptor blockade. These data establish a potential subtypes through which it may act in the 1-methyl-4-phenyl- neural basis for the inverse association of caffeine with the devel- 1,2,3,6-tetrahydropyridine (MPTP) neurotoxin model of PD. opment of PD, and they enhance the potential of A2A antagonists Caffeine, at doses comparable to those of typical human ex- as a novel treatment for this neurodegenerative disease.
    [Show full text]
  • VDAC1 Is Essential for Neurite Maintenance and the Inhibition Of
    www.nature.com/scientificreports OPEN VDAC1 is essential for neurite maintenance and the inhibition of its oligomerization protects Received: 4 July 2019 Accepted: 4 September 2019 spinal cord from demyelination Published: xx xx xxxx and facilitates locomotor function recovery after spinal cord injury Vera Paschon1, Beatriz Cintra Morena1, Felipe Fernandes Correia1, Giovanna Rossi Beltrame1, Gustavo Bispo dos Santos2, Alexandre Fogaça Cristante2 & Alexandre Hiroaki Kihara 1 During the progression of the neurodegenerative process, mitochondria participates in several intercellular signaling pathways. Voltage-dependent anion-selective channel 1 (VDAC1) is a mitochondrial porin involved in the cellular metabolism and apoptosis intrinsic pathway in many neuropathological processes. In spinal cord injury (SCI), after the primary cell death, a secondary response that comprises the release of pro-infammatory molecules triggers apoptosis, infammation, and demyelination, often leading to the loss of motor functions. Here, we investigated the functional role of VDAC1 in the neurodegeneration triggered by SCI. We frst determined that in vitro targeted ablation of VDAC1 by specifc morpholino antisense nucleotides (MOs) clearly promotes neurite retraction, whereas a pharmacological blocker of VDAC1 oligomerization (4, 4′-diisothiocyanatostilbene-2, 2′-disulfonic acid, DIDS), does not cause this efect. We next determined that, after SCI, VDAC1 undergoes conformational changes, including oligomerization and N-terminal exposition, which are important steps in the triggering of apoptotic signaling. Considering this, we investigated the efects of DIDS in vivo application after SCI. Interestingly, blockade of VDAC1 oligomerization decreases the number of apoptotic cells without interfering in the neuroinfammatory response. DIDS attenuates the massive oligodendrocyte cell death, subserving undisputable motor function recovery. Taken together, our results suggest that the prevention of VDAC1 oligomerization might be benefcial for the clinical treatment of SCI.
    [Show full text]
  • Erythroid and Megakaryocytic Transformation
    Oncogene (2007) 26, 6803–6815 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW Erythroid and megakaryocytic transformation A Wickrema1 and JD Crispino2 1Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA and 2Division of Hematology/Oncology, Northwestern University, Chicago, IL, USA Red blood cells and megakaryocytes arise from a common Accumulated evidence mostly from studies with precursor, the megakaryocyte-erythroid progenitor and mouse models and human primary cells suggests that share many regulators including the transcription factors cellular expansion and differentiation occur concur- GATA-1 and GFI-1B and signaling molecules such as JAK2 rently until the late stages of erythroid differentiation and STAT5. These lineages also share the distinction (polychromatic/orthochromatic) at which point the cells of being associated with rare, but aggressive malignancies exit the cell cycle and undergo terminal maturation that have very poor prognoses. In this review, we (Wickrema et al., 1992; Ney and D’Andrea, 2000; will briefly summarize features of normal development of Koury et al., 2002). A disruption of the balance between red blood cells and megakaryocytes and also highlight erythroid cell expansion and differentiation results in events that lead to their leukemic transformation. It is either myeloproliferative disorders (MPDs) such as clear that much more work needs to be done to improve our polycythemia vera, myelodysplastic syndrome, or rarely understanding of the unique biology of these leukemias in erythroleukemia. Furthermore, some patients initially and to pave the way for novel targeted therapeutics. diagnosed with MPDs ultimately progress to erythro- Oncogene (2007) 26, 6803–6815; doi:10.1038/sj.onc.1210763 leukemia.
    [Show full text]